nbsp;

Industrial Biotechnology (BT_MA16_2_4)

Studiengang
  • Masterstudiengang Biotechnologie
Kennzahl der Lehrveranstaltung
  • BT_MA16_2_4
Niveau der Lehrveranstaltung laut Lehrplan
  • Master
Studienjahr
  • Fall 2024
Semester in dem die Lehrveranstaltung angeboten wird
  • 3
Anzahl der zugewiesenen ECTS-Credits
  • 3.0
Name des/der Vortragenden
  • Dr. König Burghard
Lernergebnisse der Lehrveranstaltung
  • Derzeit nur in Englisch verfügbar
    Based on the elementary biochemical, molecularbiological and chemical engineering priciples the students will learn how biotechnological processes for industrial use are designed, optimized and put into operation also in large scale. They will be familiarized with fermantation processes, biotechnologically produced products and enzymes as well as their downstream-processes and the necessary technical equipments. This will include modern methods for metabolic engineering and recombinant DNA-technology for enzyme-, strain- and process-optimization. On the examples of several biotechnologically produced products like antibiotics, amino acids, steroids and biopharmaceuticals like human insulin the students get to know process optimizations as they have been used in the industrial reality.

    In times of Corona-infections the students will also learn which great challenges had to be handled and overcome to develop effective mRNA-vaccines in the short time of 2020 – 2021 by BionTech-Pfizer and Moderna, how these vaccines are produced and how the clinical tests were prepared and handled together with the regulatory authorities. This needed the entire toolbox of up-to-date biotechnology.
Art der Veranstaltung
  • face-to-face
Voraussetzungen laut Lehrplan
  • Derzeit nur in Englisch verfügbar
    BVT, MBT, BA, BTV
empfohlene optionale Programmeinheiten
  • Derzeit nur in Englisch verfügbar
    none
Lehrinhalte
  • Derzeit nur in Englisch verfügbar
    Applied Fermentation Technology and Kinetics
    • Metabolic Engineering
    • Production of Antibiotics, Amino Acids, BioPharmaceuticals and Vaccines
    • Downstream Processing Techniques for High and Low Molecular Weight Products
    • Technical Evolution of Bioprocesses
    • Rational Design of Bioprocesses
    • Industrial Biotransformations

    The diverse facets of Industrial Biotechnology will be presented on examples of real industrial processes and their additional needs in comparison to text-book publications. After an overview of modern biotechnological products in everyday life highly complex molecules will be adressed which can only be produced economically by fermentation of microorganisms and / or chemoenzymatic conversions. Therefore large-scale industrial fermentations and their control and optimization will be covered in detail. Especially the chemically very sensitive beta-lactam-antibiotics penicillin and cephalosporin will be presented from fermentation via downstream-processing to the production of their key intermediates 6-APA and 7-ACA. These antibiotics and key intermediates were already produced in the 1950th and 1960th with the help of enzymes due to their chemical sensitivity. The development of such chemoenzymatic processes, enzyme improvement, isolation and immobilization techniques will be discussed . As example for semisynthetic antibiotics the development of production processes for chiral molecule amoxycillin are trained including the switch-over from a highly pollutant chemical to a very elegant enzymatic synthesis-process.
    Semisynthetic beta-lactam antibiotics and their production processes have seen numerous development- and optimization phases due to pharmacological-, feasibility-, quality-, cost- and environmental-reasons. Molecule structures had to be modified due to up-coming resistances against beta-lactam antibiotics, especially MRSA ( methicillin resistant staphylococcus aureus ). One development were combination products of „old penicillins“ with beta-lactamase-inhibitors like amoxycillin / clavulanic acid and brand-new also with semisynthetic cephalosporins like ceftazidime / avibactam.
    On the example of the development and optimization of the Hoechst human insulin E. coli process improvement potentials in industrial biotechnology will be trained on all elements of the value chain including the use of protein-sequence specific process enzymes As latest example the important development of the mRNA-vaccines by BionTech / Pfizer and Moderna and their production process will be presented and discussed .
    Dr. Koenig has been working for more than 40 years in large scale-productions plants of the Biotech-industry and Big Pharma, was project-leader for the recombinant human insulin E. coli process of Hoechst and later production head for antibiotics. before he was also involved in the development of newer chemoenzymatic processes for several pharmaceuticals.
empfohlene Fachliteratur
  • Derzeit nur in Englisch verfügbar
    Renneberg, R.: Biotechnologie für Einsteiger, Spektrum Akademischer Verlag, 2019
    Haas, Pörtner Praxis der Bioprozesstechnik Spektrum Akad. Verlag 2011
    Thieman, W. und Palladino M.: Introduction to Biotechnology, Pearson, 2019
    Brakmann, S. Evolutionary Methods in Biotechnology Wiley VCH 2004
    Berg, J.M. et al: Biochemie, Springer Spektrum, 2018
    Horton, H.R. et al: Biochemie, Pearson Studium, 2008
    Buchholz, K. et al.: Biocatalysts and Enzyme Technology, Wiley-VCH, 2012
    Liese, A., Wandrey, C. Industrial Biotransformations Wiley-VCH, 2006
    Bommarius, A.S. und Riebel-Bommarius, B.R.: Biocatalysis, Wiley-VCH, 2004
    Storhas, W.: Bioverfahrensentwicklung, Wiley-VCH, 2006
    Wink, M.: An introduction to molecular biotechnology, Wiley-VCH, 2006
Lehr- und Lernformen
  • Derzeit nur in Englisch verfügbar
    The lecture will take place Face-to-face again and will be supplemented by tutorials for the students and discussion of their results
Prüfungsmethode
  • Exam
Unterrichtssprache
  • English
Praktikum
  • none
Zurück zur Übersicht